68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Related Clinical Trial
Propranolol and Von Hippel-Lindau Disease Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Assessment of Residual VHL Function in Tumors – Can it Predict the Patients’ Individual Course of Disease? Phase II Study of Vandetanib in Individuals With Kidney Cancer A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma Drivers of Hypoxia-induced Angiogenesis in Tumor Development Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors MyVHL: Patient Natural History Study Metabolic Mapping to Measure Retinal Metabolism Use of Tracking Devices to Locate Abnormalities During Invasive Procedures National Eye Institute Biorepository for Retinal Diseases Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Pazopanib in Von Hippel-Lindau (VHL) Syndrome 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Von Hippel-Lindau Disease Genetic Epidemiology Study Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 TKI 258 in Von Hippel-Lindau Syndrome (VHL) Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

Brief Title

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Official Title

An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC

Brief Summary

      This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission
      tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine
      tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic
      procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.

Detailed Description


      I. To substitute 68Ga-DOTATOC for 111In-pentetreotide on an expanded access basis, in tumor
      imaging for study subjects, where the care provider believes that somatostatin imaging is
      clinically indicated, until such time as 68Ga-DOTATOC becomes commercially available.


      I. To gain experience in the utility of 68Ga-DOTATOC in the management of neuroendocrine
      tumors at The University of Texas M.D. Anderson Cancer Center (MDACC).

      II. To acquire proficiency in generating 68Ga-DOTATOC for human use at MDACC.


      Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants
      undergo PET/CT scan over 60 minutes.

      After completion of study, participants are followed up at 24 hours or within 72 hours, and
      at 30 days.

Study Phase

Early Phase 1

Study Type


Primary Outcome

Incidence of adverse events




Computed Tomography

Study Arms / Comparison Groups

 Diagnostic (gallium Ga 68-edotreotide, PET/CT)
Description:  Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 16, 2017

Completion Date

February 5, 2021

Primary Completion Date

February 5, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Ability of the subject, or the legally authorized representative (LAR), if the patient
             is deemed by the treating physician to be cognitively impaired or questionably
             impaired in such a way that the ability of the patient to give informed consent is
             questionable, to understand, and the willingness to sign, a written informed consent

          -  All participants must meet one of the following:

               -  Patients diagnosed or suspected to have neuroendocrine tumors (NET), who require
                  111In-pentetreotide imaging for clinical indications

               -  Subjects with a high risk of NET because of familial predisposition, and also
                  have clinical findings which require radiolabeled somatostatin imaging

               -  Other somatostatin-positive tumors for which 111In-pentetreotide has been used
                  successfully, such as adult meningiomas

               -  Patients with suspected neuroendocrine tumor, unknown primary NET, metastatic
                  NET, or other tumors, such as meningiomas, in whom the primary physician
                  considers somatostatin imaging to be clinically indicated

               -  Other NET subjects, whether asymptomatic or symptomatic, sporadic or familial,
                  such as Von Hippel-Lindau syndrome (VHL) and multiple endocrine neoplasia type 1
                  (MEN1), will also be included

        Exclusion Criteria:

          -  Pregnant women are excluded from this study because the effects of 68Ga-DOTATOC in
             pregnancy are not known; exceptions may be granted only if the expected risk outweighs
             the benefit, in the clinical opinion of the attending physician. Pregnancy testing
             will follow MD Anderson procedure for diagnostic reagents. Self-reporting is used to
             assess pregnancy status. If the subject is unsure about her status, a urine or serum
             pregnancy test will be performed before inclusion

          -  Lactating women are excluded if patient is unwilling to suspend lactation for at least
             one day following the administration of 68Ga-DOTATOC to the mother, because of the
             unknown but potential risk for adverse events in nursing infants secondary to
             administration of the radionuclide to a lactating woman

          -  Subjects with known contraindications to the use of 111In-pentetreotide

          -  Known severe allergy or hypersensitivity to oral contrast precludes administration of
             oral contrast only

          -  Patients with a body weight of 400 pounds or more, or a body mass index (BMI) which
             precludes their entry into the bore of the PET/CT scanner, because of the resulting
             probable compromise in image quality with CT, PET/CT and magnetic resonance imaging

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the investigator may significantly interfere with
             study compliance




N/A - N/A

Accepts Healthy Volunteers



Homer A Macapinlac, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

M.D. Anderson Cancer Center


 National Cancer Institute (NCI)

Study Sponsor

Homer A Macapinlac, MD, Principal Investigator, M.D. Anderson Cancer Center

Verification Date

February 2021